NCT03721978 2024-10-17
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
Inovio Pharmaceuticals
Phase 3 Completed
Clinical Trials
10 trialsNCT03185013 2023-07-27
REVEAL 1
Inovio Pharmaceuticals
Phase 3 Completed
NCT03499795 2023-07-14
VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
Inovio Pharmaceuticals
Phase 2 Completed
NCT03697226 2021-01-13
Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection.
Antiva Biosciences
Phase 1 Completed
NCT03239223 2019-07-10
Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection
Antiva Biosciences
Phase 1 Completed
NCT02631863 2019-07-08
Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT03202992 2019-02-07
Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection
Antiva Biosciences
Phase 1 Completed
NCT02189161 2016-07-14
A Safety and Tolerability of Circumferential Anal Canal Radiofrequency Ablation For Anal Intraepithelial Neoplasia
Medtronic - MITG
Phase NA Completed
NCT00285207 2010-10-11
Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix
Tigris Pharmaceuticals
Phase 2 Completed
NCT00596258 2009-05-22
TG-003
Tigris Pharmaceuticals
Phase 2 Completed